The double ring, spool-like structure of RAD52 protects replicating DNA in dividing cells. A study led by the University of ...

This ability is similar to the action of the first drugs approved to target BRCA1/2 deficient cancers, the so-called PARP (poly-ADP-ribose polymerase) inhibitors, which are now in clinical use. While ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

the CHMP has said it recommends limiting use of Akeega to patients with BRCA1/2 mutations, which will put the drug at a disadvantage against AstraZeneca and Merck & Co’s rival PARP inhibitor ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

also form the basis of a new marketing application for the PARP inhibitor in mCRPC patients, to try to extend its uses. However, the benefit in TRITON3 was almost exclusively in the BRCA-positive ...

Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...